[CAS NO. 1093403-33-8] SRT2104 (GSK2245840)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1093403-33-8]
Catalog
SLK-S7792
Brand
Selleck
CAS
1093403-33-8
DESCRIPTION [1093403-33-8]
Overview
| MDL | MFCD22572733 |
|---|---|
| Molecular Weight | 516.64 |
| Molecular Formula | C26H24N6O2S2 |
| SMILES | O=C(C1=C(C)N=C(C2=CC=CN=C2)S1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCOCC6)=N4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9356 mL | 9.6779 mL | 19.3558 mL |
| 5 mM | 0.3871 mL | 1.9356 mL | 3.8712 mL |
| 10 mM | - | - | - |
| 50 mM | - | - | - |
Description
SRT2104 (GSK2245840) is a selective activator involved in the regulation of energy homeostasis. Phase 2.
Targets
| SIRT1 [1] |
In vitro
SRT2104 reduces p65/RelA acetylation levels in C2C12 cells.
In vivo
In male C57BL/6J mice, SRT2104 (100 mg/kg, p.o.) extends both mean and maximal lifespan of mice fed a standard diet, and enhances motor coordination, bone mineral density, and insulin sensitivity and decreased inflammation. Short-term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. In Male N171-82Q HD mice, SRT2104 (diet containing 0.5% SRT2104) effectively penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival.
References
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.